$110 Million is the total value of Abingworth LLP's 16 reported holdings in Q4 2018. The portfolio turnover from Q3 2018 to Q4 2018 was 12.5% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| CRSP | Sell | Crisprnamen akt | $33,463,000 | -39.0% | 1,171,268 | -5.3% | 30.40% | -6.8% |
| SIEN | Sientra | $27,971,000 | -46.7% | 2,199,012 | 0.0% | 25.42% | -18.6% | |
| VRNA | Veronasponds adr | $8,117,000 | -28.0% | 901,943 | 0.0% | 7.38% | +10.0% | |
| SLNO | New | Soleno | $7,984,000 | – | 4,669,272 | +100.0% | 7.25% | – |
| CHMA | Chiasma | $6,096,000 | -18.6% | 2,080,595 | 0.0% | 5.54% | +24.4% | |
| OBSV | Obseva | $5,566,000 | -29.9% | 440,000 | 0.0% | 5.06% | +7.2% | |
| PRTK | Paratek | $5,341,000 | -46.8% | 1,041,131 | 0.0% | 4.85% | -18.8% | |
| PRTO | Proteon | $4,581,000 | +19.5% | 2,017,872 | 0.0% | 4.16% | +82.6% | |
| AUPH | Aurinia Pharma | $2,723,000 | +2.6% | 400,434 | 0.0% | 2.47% | +56.8% | |
| SRRA | Sierra Oncology | $1,892,000 | -23.0% | 1,444,445 | 0.0% | 1.72% | +17.7% | |
| CLLS | Cellectissponds adr | $1,664,000 | -41.1% | 100,000 | 0.0% | 1.51% | -9.9% | |
| RARE | Ultragenyx | $1,656,000 | -43.1% | 38,100 | 0.0% | 1.50% | -13.0% | |
| ADAP | Adaptimmunesponds adr | $1,438,000 | -57.6% | 250,000 | 0.0% | 1.31% | -35.1% | |
| CBAY | Sell | Cymabay | $1,030,000 | -66.0% | 131,036 | -52.1% | 0.94% | -48.0% |
| IMDZ | Immune Design | $458,000 | -61.8% | 352,300 | 0.0% | 0.42% | -41.6% | |
| HSGX | Histogenics | $77,000 | -83.7% | 888,889 | 0.0% | 0.07% | -75.1% | |
| AVEO | Exit | Aveo Pharma | $0 | – | -400,000 | -100.0% | -0.78% | – |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2019-02-14
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| SIENTRA INC | 33 | Q4 2022 | 31.2% |
| PARATEK PHARMACEUTICALS INC | 33 | Q4 2022 | 24.9% |
| CYMABAY THERAPEUTICS INC | 30 | Q4 2022 | 8.6% |
| Ocugen | 24 | Q2 2022 | 1.5% |
| Proteon | 22 | Q3 2020 | 18.9% |
| OBSEVA SA | 22 | Q4 2022 | 5.1% |
| Chiasma | 19 | Q1 2020 | 24.6% |
| VERONA PHARMA PLC | 18 | Q4 2022 | 20.9% |
| Sierra Oncology | 18 | Q2 2022 | 23.1% |
| Crispr | 16 | Q3 2020 | 53.6% |
View Abingworth LLP's complete holdings history.
Latest significant ownerships (13-D/G)
| Filed | Shares | Percentage | |
|---|---|---|---|
| Verona Pharma plc | August 11, 2022 | 21,313,822 | 4.4% |
| Sierra Oncology, Inc.Sold out | July 11, 2022 | 0 | 0.0% |
| HilleVax, Inc. | May 13, 2022 | 1,838,486 | 5.5% |
| SOLENO THERAPEUTICS INC | April 08, 2022 | 18,368,373 | 15.3% |
| Vera Therapeutics, Inc. | April 07, 2022 | 2,970,156 | 11.1% |
| EXICURE, INC. | February 25, 2022 | 7,084,297 | 6.5% |
| Vaxcyte, Inc. | February 14, 2022 | 4,183,716 | 7.9% |
| Jasper Therapeutics, Inc. | October 04, 2021 | 5,628,558 | 15.4% |
| eFFECTOR Therapeutics, Inc. | September 03, 2021 | 4,822,114 | 11.9% |
| Reneo Pharmaceuticals, Inc. | April 20, 2021 | 1,858,226 | 7.7% |
View Abingworth LLP's complete significant-ownership history.
Latest filings
| Type | Filed |
|---|---|
| 13F-NT | 2024-05-03 |
| 4 | 2024-02-12 |
| 13F-NT | 2024-02-02 |
| 13F-NT | 2023-11-03 |
| 4 | 2023-10-02 |
| 13F-NT | 2023-08-04 |
| 4 | 2023-05-10 |
| 13F-NT | 2023-05-05 |
| 13F-HR | 2023-02-10 |
| 4 | 2023-01-31 |
View Abingworth LLP's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.